Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Osimertinib Tablets bulk supplier for pharma manufacturers

Osimertinib Tablets 40mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 40mg

Reference Brands: Tagrisso (USA/EU)

Category: Oncology Cancer Care

Osimertinib is used to treat metastatic (cancer that has already spread) non-small cell lung cancer in patients who have certain types of abnormal epidermal growth factor (EGFR) genes.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

-

Osimertinib Tablets — third party manufacturing & bulk supply

Osimertinib Tablets 40mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Indicative minimum order quantity

Osimertinib Tablets is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Osimertinib Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Osimertinib Tablets →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Osimertinib Tablets is listed as Tablets in 40mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Osimertinib Tablets is referenced against Tagrisso (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.

Osimertinib Tablets is catalogued under Oncology Cancer Care on PharmaTradz. Related products within the same category are listed at the foot of this page.

Submit an RFQ stating your destination market, required quantity and whether you need stock supply, third party manufacturing or dossier licensing. Matched suppliers respond with pricing, MOQ and lead times.

Related Products

Fruquin 5 Mg (Fruquintinib)

Strength:
5 Mg

Form: Capsules

Reference Brands: Everest Bangladesh altd.

View Details
Vorinostat

Strength:
100 mg

Form: Capsules

Reference Brands: Zolinza (USA/EU), Vornat (India)

View Details
Panobinostat Lactate

Strength:
10 mg, 15 mg, 20 mg

Form: Capsules

Reference Brands: Farydak (USA/EU),

View Details
Gilteritinib

Strength:
40 mg

Form: Tablets

Reference Brands: Xospata (USA/India), LuciGil (Asia)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.